Inaktiver Wert

Andere Sprachen BioTime, Inc. Nyse

Aktien

US09066L1052

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

Lineage Cell Therapeutics : Immediate Report	11.05.
Lineage Cell: Q1 Earnings Snapshot	09.05.
Earnings Flash (LCTX) LINEAGE CELL THERAPEUTICS Reports Q1 Revenue $1.4M, vs. Street Est of $1.36M	09.05.
Lineage Cell Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update	09.05.
LINEAGE CELL - OPREGEN PHASE 1/2A CLINICAL STUDY 24-MONTH VISUAL ACUITY RESULTS FEATURED AT 2024 RETINAL CELL AND GENE THERAPY INNOVATION SUMMIT	07.05.
OpRegen® (RG6501) Phase 1/2a Clinical Study 24-Month Visual Acuity Results Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit	06.05.
Lineage Cell Therapeutics, Inc. Announces 24 Month Visual Acuity Results Featured At 2024 Retinal Cell & Gene Therapy Innovation Summit	06.05.
Lineage Cell Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024	02.05.
LINEAGE RECEIVES GRANT FROM CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE	01.05.
Lineage Cell Therapeutics : Immediate Report	30.04.
Lineage Cell Therapeutics : Additional proxy soliciting materials - definitive	30.04.
Lineage Cell Therapeutics : NOTICE OF ANNUAL MEETING OF SHAREHOLDERS TO BE HELD ON JUNE 11, 2024, PROXY	30.04.
Lineage Receives Grant From California Institute for Regenerative Medicine (CIRM)	30.04.
Lineage Announces Changes to Board of Directors	29.04.
Lineage Cell Therapeutics, Inc. Announces Changes to Board of Directors	29.04.
Lineage Announces Appointment of Charlotte Hubbert, Ph.D., as Vice President of Corporate Development	01.04.
Lineage Cell Therapeutics : Immediate Report	24.03.
Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 2nd Annual Spinal Cord Injury Investor Symposium	18.03.
LINEAGE CELL THERAPEUTICS, INC. - RG6501 PHASE 1/2A CLINICAL STUDY 24 MONTH RESULTS TO BE FEATURED AT 2024 RETINAL CELL AND GENE THERAPY INNOVATION SUMMIT	14.03.
RG6501 (OpRegen®) Phase 1/2a Clinical Study 24 Month Results to Be Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit	13.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen BioTime, Inc. Nyse

Aktien

US09066L1052

Andere Sprachen

Filter